KR101816953B1 - １-[２-(２,４-디메틸-페닐술파닐)페닐]-피페라진의 치료적 용도 - Google Patents

１-[２-(２,４-디메틸-페닐술파닐)페닐]-피페라진의 치료적 용도 Download PDF

Info

Publication number
KR101816953B1
KR101816953B1 KR1020137004481A KR20137004481A KR101816953B1 KR 101816953 B1 KR101816953 B1 KR 101816953B1 KR 1020137004481 A KR1020137004481 A KR 1020137004481A KR 20137004481 A KR20137004481 A KR 20137004481A KR 101816953 B1 KR101816953 B1 KR 101816953B1
Authority
KR
South Korea
Prior art keywords
delete delete
treatment
compound
patient
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137004481A
Other languages
English (en)
Korean (ko)
Other versions
KR20130097162A (ko
Inventor
마리안네 드라게임
이오아나 프로레아
Original Assignee
하. 룬드벡 아크티에셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44532506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101816953(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 하. 룬드벡 아크티에셀스카브 filed Critical 하. 룬드벡 아크티에셀스카브
Publication of KR20130097162A publication Critical patent/KR20130097162A/ko
Application granted granted Critical
Publication of KR101816953B1 publication Critical patent/KR101816953B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020137004481A 2010-08-23 2011-08-22 １-[２-(２,４-디메틸-페닐술파닐)페닐]-피페라진의 치료적 용도 Active KR101816953B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37588510P 2010-08-23 2010-08-23
DKPA201000739 2010-08-23
US61/375,885 2010-08-23
DKPA201000739 2010-08-23
PCT/DK2011/050317 WO2012025123A1 (en) 2010-08-23 2011-08-22 Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine

Publications (2)

Publication Number Publication Date
KR20130097162A KR20130097162A (ko) 2013-09-02
KR101816953B1 true KR101816953B1 (ko) 2018-01-09

Family

ID=44532506

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137004481A Active KR101816953B1 (ko) 2010-08-23 2011-08-22 １-[２-(２,４-디메틸-페닐술파닐)페닐]-피페라진의 치료적 용도

Country Status (32)

Country Link
US (5) US20130184291A1 (enExample)
EP (1) EP2608789B2 (enExample)
JP (1) JP5902169B2 (enExample)
KR (1) KR101816953B1 (enExample)
CN (1) CN103068389A (enExample)
AP (1) AP3583A (enExample)
AR (1) AR082501A1 (enExample)
AU (1) AU2011295465B8 (enExample)
BR (2) BR112013002194A2 (enExample)
CA (1) CA2807062C (enExample)
CL (1) CL2013000492A1 (enExample)
CO (1) CO6680652A2 (enExample)
CY (1) CY1118886T1 (enExample)
DK (1) DK2608789T4 (enExample)
ES (1) ES2625142T5 (enExample)
FI (1) FI2608789T4 (enExample)
HR (1) HRP20170608T4 (enExample)
HU (1) HUE034155T2 (enExample)
IL (1) IL224371A (enExample)
LT (1) LT2608789T (enExample)
ME (1) ME02674B (enExample)
MX (1) MX349724B (enExample)
PL (1) PL2608789T5 (enExample)
PT (1) PT2608789T (enExample)
RS (1) RS55851B2 (enExample)
RU (1) RU2564666C2 (enExample)
SG (1) SG187649A1 (enExample)
SI (1) SI2608789T2 (enExample)
SM (1) SMT201700239T1 (enExample)
TW (1) TW201212918A (enExample)
WO (1) WO2012025123A1 (enExample)
ZA (1) ZA201301385B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA029060B1 (ru) 2014-01-31 2018-02-28 Эгиш Дьёдьсердьяр Зрт. Способ получения солей вортиоксетина
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
US9820984B1 (en) 2016-07-01 2017-11-21 H. Lundbeck A/S Dosing regimens for fast onset of antidepressant effect
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
ATE138374T1 (de) * 1991-11-18 1996-06-15 Lilly Industries Ltd Benzo(b)thiophen-2-carboxamide zur behandlung von krankheiten des zentralnervensystems
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
EP1322854A4 (en) 2000-10-02 2004-08-04 Rohr Inc APPARATUS, METHOD AND SYSTEM FOR REDUCING THE NOISE OF A GAS TURBINE
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US8722684B2 (en) 2006-06-16 2014-05-13 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
F. Artigas 외 4명. A randomised, double-blind, placebo-controlled, active-referenced study of Lu AA21004 in patients with major depression. EuropeanNeuropsychopharmacology. Vol.19. pp.S426~S427. (2009)*

Also Published As

Publication number Publication date
DK2608789T3 (en) 2017-05-15
US20210085674A1 (en) 2021-03-25
AP3583A (en) 2016-02-09
MX2013001570A (es) 2013-03-21
EP2608789B1 (en) 2017-04-12
RU2013112890A (ru) 2014-09-27
EP2608789B2 (en) 2024-08-21
JP5902169B2 (ja) 2016-04-13
RU2564666C2 (ru) 2015-10-10
CN103068389A (zh) 2013-04-24
US20240293397A1 (en) 2024-09-05
BR112013002194A2 (pt) 2016-05-31
AU2011295465B2 (en) 2014-06-19
ZA201301385B (en) 2014-04-30
RS55851B2 (sr) 2024-11-29
ES2625142T3 (es) 2017-07-18
JP2013536206A (ja) 2013-09-19
LT2608789T (lt) 2017-05-25
KR20130097162A (ko) 2013-09-02
PL2608789T5 (pl) 2025-11-12
ME02674B (me) 2017-06-20
IL224371A (en) 2016-07-31
PT2608789T (pt) 2017-05-26
CA2807062A1 (en) 2012-03-01
AU2011295465A1 (en) 2013-02-07
US20190000836A1 (en) 2019-01-03
RS55851B1 (sr) 2017-08-31
TW201212918A (en) 2012-04-01
SMT201700239T1 (it) 2017-07-18
ES2625142T5 (en) 2025-02-10
AU2011295465B8 (en) 2014-07-10
EP2608789A1 (en) 2013-07-03
US20220370439A1 (en) 2022-11-24
DK2608789T4 (da) 2024-11-04
BR122020025600A2 (pt) 2021-01-05
PL2608789T3 (pl) 2017-09-29
CL2013000492A1 (es) 2013-06-07
AR082501A1 (es) 2012-12-12
US20130184291A1 (en) 2013-07-18
CA2807062C (en) 2018-07-31
WO2012025123A1 (en) 2012-03-01
SI2608789T2 (sl) 2025-05-30
CY1118886T1 (el) 2018-01-10
FI2608789T4 (fi) 2024-11-01
HRP20170608T4 (hr) 2024-12-06
HUE034155T2 (en) 2018-01-29
AP2013006768A0 (en) 2012-03-31
SG187649A1 (en) 2013-03-28
SI2608789T1 (sl) 2017-06-30
CO6680652A2 (es) 2013-05-31
HRP20170608T1 (hr) 2017-07-28
MX349724B (es) 2017-08-10

Similar Documents

Publication Publication Date Title
US20240293397A1 (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
US20190290603A1 (en) Titration of tapentadol
US20090023744A1 (en) Combination therapy for depression
HK1184374A (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
CN114080221B (zh) 用于减轻疼痛的布洛芬与曲马多的组合
HK40067137B (en) Combination of ibuprofen and tramadol for relieving pain
US20130150375A1 (en) GEPIRONE-ER TREATMENT OF MAJOR DEPRESSION IN PATIENTS TAKING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9